The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Designer lipids for drug delivery: From heads to tails
Open accessAbstract
For four decades, liposomes composed of both naturally occurring and synthetic lipids have been investigated as delivery vehicles for low molecular weight and macromolecular drugs. These studies paved the way for the clinical and commercial success of a number of liposomal drugs, each of which required a tailored formulation; one liposome size does not fit all drugs! Instead, the physicochemical properties of the liposome must be matched to the pharmacology of the drug. An extensive biophysical literature demonstrates that varying lipid composition can influence the size, membrane stability, in vivo interactions, and drug release properties of a liposome. In this review we focus on recently described synthetic lipid headgroups, linkers and hydrophobic domains that can provide control over the intermolecular forces, phase preference, and macroscopic behavior of liposomes. These synthetic lipids further our understanding of lipid biophysics, promote targeted drug delivery, and improve liposome stability. We further highlight the immune reactivity of novel synthetic headgroups as a key design consideration. For instance it was originally thought that synthetic PEGylated lipids were immunologically inert; however, it’s been observed that under certain conditions PEGylated lipids induce humoral immunity. Such immune activation may be a limitation to the use of other engineered lipid headgroups for drug delivery. In addition to the potential immunogenicity of engineered lipids, future investigations on liposome drugs in vivo should pay particular attention to the location and dynamics of payload release.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Doxil®, a liposomal doxorubicin formulation incorporating PEG-2000-1,2distearoyl-sn-glycero-3-phosphoethanolamine (PEG2000-DSPE) is the only FDA approved PEGylated liposomal therapeutic [19,20]; its development was recently reviewed [21].”
BackgroundToxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · cited 2×
“Subsequent injections are then labeled for removal and are rapidly cleared from circulation and accumulate largely in the liver and spleen [24,25].”
BackgroundPEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Ishida, T., Wang, X., Shimizu, T., Nawata, K., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.015 · Cited by 382
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s
Gaertner, F. C., Luxenhofer, R., Blechert, B., Jordan, R., & Essler, M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.015 · Cited by 255
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Moysan, E., Bastiat, G., & Benoit, J.-P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300370t · Cited by 225
Hamilton, J. A. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200306000-00006 · Cited by 184
Self-Adjuvanting Lipopeptide Vaccines
Moyle, P., & Toth, I. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503249 · Cited by 155
Cited by
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
“Under the physiological pH, different head groups provide liposomes with negative (PA, PS, PG, and cardiolipin) or neutral (PC and PE) charges [49].”
BackgroundLiposomes and polymersomes: a comparative review towards cell mimicking
Rideau, E., Dimova, R., Schwille, P., Wurm, F. R., & Landfester, K. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00162f · Cited by 1,105
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Immunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Metadata
- Authors
- Kohli, A. G., Kierstead, P. H., Venditto, V. J., Walsh, C. L., & Szoka, F. C.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 190
- Pages
- 274-287
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1974913887
- Cited by
- 167
- References
- 12
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.